Back to Top Skip to main content Skip to sub-navigation

Military Health System participating in COVID-19 vaccine trial

Woman measuring out a vaccine into a needle Five military medical treatment facilities are participating in a Phase 3 clinical trial testing a COVID-19 vaccine in development with AstraZeneca. (Photo by Air Force Staff Sgt. Joshua Garcia.)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | Vaccine Trials

Five military medical treatment facilities in the National Capital Region, Texas, and California are participating in a phase 3 clinical trial testing the AstraZeneca COVID-19 vaccine in development under Operation Warp Speed.  The DoD sites are actively enrolling study participants, with a goal to recruit up to 1,000 volunteers in each of the three market areas towards the total AstraZeneca clinical trial enrollment of 30,000 people.

Operation Warp Speed, a multiagency U.S. Government effort led by the Department of Health and Human Services and the Department of Defense, is working with the private sector with the aims to deliver safe and effective COVID-19 vaccine doses to the American public beginning January 2021.

OWS is funding clinical trials evaluating several vaccine candidates which were selected based on promising data on safety, immune response, and protection in animal studies and safety and immune response data in early-stage trials in humans. Each of the trials is designed to collect data on how well a vaccine candidate protects against COVID-19 and on the safety of the vaccine candidate in a larger population, including people most at risk.  

“The Department of Defense continues to play a key role in the development of a potential COVID-19 vaccine,” said Thomas McCaffery, assistant secretary of Defense for Health Affairs. “Now that vaccines have passed the first phases of testing for safety, dosing, and response, we have moved into the next phase where volunteers are needed to join large clinical studies. We are excited to have several sites supporting these next steps in the vaccine development process.”

Large phase 3 clinical trials are a necessary part of the rigorous scientific process to test the efficacy and safety of a vaccine in a real-world setting with a large population sample, said Air Force Col (Dr.) Jessica Cowden, chief medical officer of the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnology Vaccine Acceleration Project.

“Phase 3 studies are designed to evaluate if the vaccine can prevent disease in the populations of people that the vaccine is being developed to protect,” said Cowden. “Phase 3 studies are large and usually involve some people who are at risk for infection and disease.”

The National Institute of Allergy and Infectious Diseases at the National Institutes of Health established a network of infectious disease experts and research partners, termed the Coronavirus Prevention Network, or CoVPN, to rapidly and thoroughly evaluate U.S. government-sponsored COVID-19 vaccines. The CoVPN website (https://www.coronaviruspreventionnetwork.org/) provides general information about products being developed to prevent COVID-19 and about clinical trials.

According to the CoVPN, interested volunteers must be adults aged 18 and older to be screened for these initial trials. The CoVPN recognizes the importance of including volunteers who are more likely to get COVID-19, such as those over the age of 65 or with underlying medical conditions; as well as people who work in an essential job, live in a densely populated area, or represent a racial and ethnic group greatly impacted by the epidemic.

Representation by such groups matters in Phase 3 trials because vaccines need to be tested in populations who are at most risk of being exposed to the disease and getting sick in the real world, explained Cowden. “At-risk populations shouldn’t bear a disproportionate burden of research, but they need to be represented,” she said

The selected DoD sites are currently enrolling volunteers for the AstraZeneca clinical trial, according to Cowden. The trial is a randomized control, double-blind study, meaning volunteers will either receive the study vaccine or saline. “The study team and the participant will be blinded so that they won’t know which the participant received until the end of the study,” Cowden said. AstraZeneca’s vaccine candidate is in late-stage clinical trials ongoing in the U.K., Brazil and South Africa.

“Participating in a vaccine clinical trial is voluntary but is also critically vital to ensure that the overall effort is ultimately successful,” said Dr. Sean Biggerstaff, acting deputy director, DHA Research and Development Directorate. “Volunteers should also know safety remains an overriding priority for anyone participating in clinical trials.”

Military health beneficiaries who wish to volunteer for the AstraZeneca COVID-19 vaccine at a nearby military medical treatment facility (or at a civilian site close to home) can contact the local study team directly to request more information or can register on the CoVPN website and consent to be contacted by a research team. If registering on the CoVPN site, interested volunteers should enter the appropriate code in parenthesis from the list below, or enter their ZIP code to join the registry. Site contact information is included here:

At this point, the DoD is only participating in the AstraZeneca study. Additional DoD sites are being prepared for participation in other clinical trials of vaccines and monoclonal antibodies to prevent COVID-19, said Cowden.

“Having a safe and effective COVID-19 vaccine is what we need to protect people and get life back to normal, but in order to get to that point, we have to do these clinical trials,” explained Cowden. “These big Phase 3 clinical trials with a lot of people participating are critical so we can get the information we need to determine if a vaccine candidate is safe and can prevent COVID-19.”

You also may be interested in...

Army’s 773rd administers mobile COVID-19 testing during DEF21

Article
6/4/2021
Three military personnel, wearing masks and lab coats, pose for a picture in an Albanian lab.

Approximately 800 Army Reserve soldiers from the U.S. and Europe participated in DEFENDER-Europe 21.

Recommended Content:

Health Readiness | Coronavirus | COVID-19 Vaccine Toolkit | Readiness Capabilities

Mental Health Panel Discusses Impact of COVID-19

Article
6/3/2021
Military personnel wearing face mask speaking on a panel

Walter Reed Bethesda hosts mental health panel to discuss the impacts of COVID-19.

Recommended Content:

COVID-19 Vaccine Toolkit | Mental Health Awareness Month | Coronavirus | Psychological Fitness

Based on data, MHS experts encourage vaccines for adolescents

Article
6/1/2021
Sister and brother smiling at each other

With the Pfizer vaccine approved for youth ages 12 to 15, MHS adolescents are lining up to get the COVID-19 vaccine.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts | Children's Health | Vaccine Eligibility

“Shots in arms” – OPT planned & coordinated to meet COVID-19 mission

Article
5/28/2021
Military personnel sitting around a table talking

The Department of Defense’s COVID-19 Operational Planning Team has been the quiet force behind the DOD’s vaccination effort since November.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

Adolescents ages 12 and older eligible for COVID-19 vaccinations

Article
5/27/2021
Son of military personnel receiving his COVID-19 vaccine

Pfizer vaccine now authorized for children 12 and older.

Recommended Content:

Children's Health | COVID-19 Vaccine Toolkit | Coronavirus

COVID-19 Town Hall with RADM Anne M. Swap

Article
5/24/2021
MHS and Military OneSource NCR COVID-19 Town Hall with Rear Admiral Anne M. Swap, Director, National Capital Medical Directorate, Wednesday, May 26 at 11:50 a.m. ET

The purpose of this event is to inform National Capital Region (NCR) beneficiaries of DHA’s efforts with battling coronavirus (COVID-19) and encourage them to not delay care.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

Adirim, Place laud DHA response to COVID-19 in briefing

Article
5/21/2021
Defense Health Agency Director Lt. Gen. (Dr.) Ronald J. Place speaking at a press conference

Dr. Terry Adirim, acting assistant secretary of defense for health affairs, and Army Lt. Gen. (Dr.) Ronald J. Place, director of the Defense Health Agency, provided a COVID-19 update during a Pentagon press briefing.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

Sailors continue to receive COVID-19 vaccine

Article
5/20/2021
Military personnel wearing a face mask receiving the COVID-19 vaccine

Sailors continue to voluntarily receive one of the three available COVID-19 vaccines.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

MHS quickly adapted to improve patient experience during pandemic

Article
5/19/2021
Military health personnel waiting for the next phone call on the COVID-19 advice line

MHS adapted technology to boost patient experience during pandemic

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

DHA Director visits MCAGCC to hear from the ‘Boots on the Ground’

Article
5/19/2021
Military personnel wearing face masks walking

DHA Director visits Marine Corps Air Ground Combat Center Twentynine Palms.

Recommended Content:

MHS GENESIS | Military Health System Transformation | Coronavirus | COVID-19 Vaccine Toolkit

Palliative care provides comfort to COVID-19 patients, families

Article
5/17/2021
Military health personnel taking care of a patient

Medical Center team develops palliative care toolkit for COVID-19 patients

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

Military medicine heroes recognized for COVID-19 pandemic response

Article
5/17/2021
Photo of the virtual "Heroes of Military Medicine" award ceremony

COVID-19 pandemic will affect military medicine for years to come, DHA Director Place tells HJF awards ceremony.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

DHA leadership recognizes, advances 60th MDG mission

Article
5/14/2021
Army Lt. Gen. Ronald Place visits Travis Air Force Base

DHA leadership visit 60th Medical Group at Travis AFB.

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit | MHS GENESIS

Teamwork, adaptability, service – MTFs shine during COVID-19 pandemic

Article
5/14/2021
People at screening area

MHS readiness was put to the test at the onset of the COVID-19 pandemic, in early 2020.

Recommended Content:

May Toolkit | May | COVID-19 Vaccine Toolkit | Coronavirus

Join Us!! Sixth Live COVID-19 Town Hall

Article
5/12/2021
Image describing today's Town Hall with Dr. Paul Scott and COL Clinton K. Murray, MD.  They are with the Walter Reed Army Institute of Research, and will discuss COVID-19 Vaccine Advancement and Trials.

Join us for today's Town Hall with Dr. Paul Scott and COL Clinton K. Murray, MD. They are with the Walter Reed Army Institute of Research, and will discuss COVID-19 Vaccine Advancement and Trials.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 24

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.